TABLE 3.

Primary and Secondary Outcomes With Canagliflozin 100 mg (n = 7)

Baseline Mean (SD)First Follow-Up Mean (SD)Difference: Baseline to First Follow-UpPSecond Follow-Up Mean (SD)Difference: Baseline to Second Follow-UpP
A1C, %7.70 (1.04)7.11 (1.00)–0.590.002*7.03 (0.77)–0.670.016**
BMI, kg/m236.66 (5.13)35.86 (4.93)–0.800.13234.36 (3.65)–2.290.154
Weight, kg103.71 (17.64)101.76 (19.02)–1.960.20498.00 (19.57)–5.710.171
SBP, mmHg114.00 (14.51)114.00 (6.63)0.001.000116.86 (15.66)2.860.466
DBP, mmHg66.29 (13.92)67.14 (8.63)0.860.82464.86 (10.64)–1.430.783
  • * Significant at α = 0.01.

  • ** Significant at α = 0.05.